arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

TG THERAPEUTICS, INC.

TGTX
$57.95 ▼ -3.73 (-6.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

TG THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $8.4B
Dividend Yield —
Revenue Growth 87.3% ↗
Op. Margin 20.0% ↗
ROIC 57.5% ↗
FCF / Share $-0.17 ↗
Trailing P/E 18.7x
Price / Book 13.9x
FCF Yield —
Debt / Equity 0.38
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$616.29M
↑ +87.3% —
Net Income Profit after all expenses
$447.18M
↑ +1812.4% —
Operating Margin Operating profit as % of sales
20.0%
↑ +57.0% 75th
FCF / Share Free cash flow per share
$-0.17
↑ +38.0% —
Long-Term Debt Long-term obligations
$245.65M
— +0.5% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
64
Returns
98
Financial Health ↓
66
Cash Quality
20

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 82 quarters